Evofem Biosciences Inc, (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, has enrolled the first patient in its pivotal Phase three clinical trial assessing the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhoea in women, it was reported on Tuesday.

EVOGUARD is a double-blind, placebo-controlled Phase three clinical trial aimed at assessing the safety and efficacy of the product intended for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoea infection in women.

The study is to enrol 1,730 women who have had a urogenital chlamydia or gonorrhoea infection at any time over the 16 weeks preceding the enrolment visit, along with one or more risk factors for infection.